Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade

NCT ID: NCT01933425

Last Updated: 2015-03-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate if deep neuromuscular blockade improves intraabdominal volume compared to no neuromuscular blockade in patients scheduled for gynecologic laparoscopic surgery with pneumoperitoneum 12 mmHg.

Hypothesis:

Deep neuromuscular blockade improves intraabdominal space (the distance from promontorium to skin surface, cm) compared to no neuromuscular blockade.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromuscular Blockade

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deep neuromuscular block followed by no neuromuscular block

Deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg followed by no neuromuscular blockade with sugammadex 8 mg/kg and placebo reversal.

Measurements of intraabdominal distance during deep neuromuscular blockade and without neuromuscular blockade

Group Type ACTIVE_COMPARATOR

rocuronium

Intervention Type DRUG

sugammadex

Intervention Type DRUG

placebo

Intervention Type DRUG

No neuromuscular block followed by deep neuromuscular block

No neuromuscular blockade with placebo followed by deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg and reversal with sugammadex 8 mg/kg.

Measurements of intraabdominal distance during no neuromuscular blockade and during deep neuromuscular blockade.

Group Type PLACEBO_COMPARATOR

rocuronium

Intervention Type DRUG

sugammadex

Intervention Type DRUG

placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rocuronium

Intervention Type DRUG

sugammadex

Intervention Type DRUG

placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients \> 18 years old
* elective laparoscopic operation
* can read and understand Danish
* informed consent

Exclusion Criteria

* BMI \> 30 kg/cm2
* known allergy to medications that are included in the project,
* severe renal disease, defined by S-creatinine\> 0,200 mmol/L, GFR \< 30ml/min or hemodialysis),
* neuromuscular disease that may interfere with neuromuscular data,
* lactating or pregnant,
* impaired liver function,
* converting to laparotomy,
* perioperative use of neuromuscular blocking agents before randomization,
* pneumoperitoneum set to \>12 mmHg on the insufflator
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Herlev Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Matias Vested Madsen

research assistent, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Matias Vested Madsen, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Anesthesiology Herlev Hospital

Olav Istre, MD, DMSc, professor

Role: STUDY_DIRECTOR

Department of minimal invasive gynecology, Aleris-Hamlet, Copenhagen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of minimal invasive gynecology Aleris-Hamlet Private Hospital

Copenhagen, Søborg, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-001164-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NMBDK2013

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.